Cargando…

Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice

With the rapid progress made in the development of vaccines to fight the SARS-CoV-2 pandemic, almost >90% of vaccine candidates under development and a 100% of the licensed vaccines are delivered intramuscularly (IM). While these vaccines are highly efficacious against COVID-19 disease, their eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Ganesan, Shyamala, Acosta, Hugo, Brigolin, Chris, Orange, Kallista, Trabbic, Kevin, Chen, Charles, Lien, Chia-En, Lin, Yi-Jiun, Lin, Meei-Yun, Chuang, Ya-Shan, Fattom, Ali, Bitko, Vira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629544/
https://www.ncbi.nlm.nih.gov/pubmed/36322572
http://dx.doi.org/10.1371/journal.pone.0272594
_version_ 1784823417707429888
author Ganesan, Shyamala
Acosta, Hugo
Brigolin, Chris
Orange, Kallista
Trabbic, Kevin
Chen, Charles
Lien, Chia-En
Lin, Yi-Jiun
Lin, Meei-Yun
Chuang, Ya-Shan
Fattom, Ali
Bitko, Vira
author_facet Ganesan, Shyamala
Acosta, Hugo
Brigolin, Chris
Orange, Kallista
Trabbic, Kevin
Chen, Charles
Lien, Chia-En
Lin, Yi-Jiun
Lin, Meei-Yun
Chuang, Ya-Shan
Fattom, Ali
Bitko, Vira
author_sort Ganesan, Shyamala
collection PubMed
description With the rapid progress made in the development of vaccines to fight the SARS-CoV-2 pandemic, almost >90% of vaccine candidates under development and a 100% of the licensed vaccines are delivered intramuscularly (IM). While these vaccines are highly efficacious against COVID-19 disease, their efficacy against SARS-CoV-2 infection of upper respiratory tract and transmission is at best temporary. Development of safe and efficacious vaccines that are able to induce robust mucosal and systemic immune responses are needed to control new variants. In this study, we have used our nanoemulsion adjuvant (NE01) to intranasally (IN) deliver stabilized spike protein (S-2P) to induce immunogenicity in mouse and hamster models. Data presented demonstrate the induction of robust immunity in mice resulting in 100% seroconversion and protection against SARS-CoV-2 in a hamster challenge model. There was a significant induction of mucosal immune responses as demonstrated by IgA- and IgG-producing memory B cells in the lungs of animals that received intranasal immunizations compared to an alum adjuvanted intramuscular vaccine. The efficacy of the S-2P/NE01 vaccine was also demonstrated in an intranasal hamster challenge model with SARS-CoV-2 and conferred significant protection against weight loss, lung pathology, and viral clearance from both upper and lower respiratory tract. Our findings demonstrate that intranasal NE01-adjuvanted vaccine promotes protective immunity against SARS-CoV-2 infection and disease through activation of three arms of immune system: humoral, cellular, and mucosal, suggesting that an intranasal SARS-CoV-2 vaccine may play a role in addressing a unique public health problem and unmet medical need.
format Online
Article
Text
id pubmed-9629544
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-96295442022-11-03 Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice Ganesan, Shyamala Acosta, Hugo Brigolin, Chris Orange, Kallista Trabbic, Kevin Chen, Charles Lien, Chia-En Lin, Yi-Jiun Lin, Meei-Yun Chuang, Ya-Shan Fattom, Ali Bitko, Vira PLoS One Research Article With the rapid progress made in the development of vaccines to fight the SARS-CoV-2 pandemic, almost >90% of vaccine candidates under development and a 100% of the licensed vaccines are delivered intramuscularly (IM). While these vaccines are highly efficacious against COVID-19 disease, their efficacy against SARS-CoV-2 infection of upper respiratory tract and transmission is at best temporary. Development of safe and efficacious vaccines that are able to induce robust mucosal and systemic immune responses are needed to control new variants. In this study, we have used our nanoemulsion adjuvant (NE01) to intranasally (IN) deliver stabilized spike protein (S-2P) to induce immunogenicity in mouse and hamster models. Data presented demonstrate the induction of robust immunity in mice resulting in 100% seroconversion and protection against SARS-CoV-2 in a hamster challenge model. There was a significant induction of mucosal immune responses as demonstrated by IgA- and IgG-producing memory B cells in the lungs of animals that received intranasal immunizations compared to an alum adjuvanted intramuscular vaccine. The efficacy of the S-2P/NE01 vaccine was also demonstrated in an intranasal hamster challenge model with SARS-CoV-2 and conferred significant protection against weight loss, lung pathology, and viral clearance from both upper and lower respiratory tract. Our findings demonstrate that intranasal NE01-adjuvanted vaccine promotes protective immunity against SARS-CoV-2 infection and disease through activation of three arms of immune system: humoral, cellular, and mucosal, suggesting that an intranasal SARS-CoV-2 vaccine may play a role in addressing a unique public health problem and unmet medical need. Public Library of Science 2022-11-02 /pmc/articles/PMC9629544/ /pubmed/36322572 http://dx.doi.org/10.1371/journal.pone.0272594 Text en © 2022 Ganesan et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Ganesan, Shyamala
Acosta, Hugo
Brigolin, Chris
Orange, Kallista
Trabbic, Kevin
Chen, Charles
Lien, Chia-En
Lin, Yi-Jiun
Lin, Meei-Yun
Chuang, Ya-Shan
Fattom, Ali
Bitko, Vira
Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice
title Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice
title_full Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice
title_fullStr Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice
title_full_unstemmed Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice
title_short Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice
title_sort intranasal nanoemulsion adjuvanted s-2p vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629544/
https://www.ncbi.nlm.nih.gov/pubmed/36322572
http://dx.doi.org/10.1371/journal.pone.0272594
work_keys_str_mv AT ganesanshyamala intranasalnanoemulsionadjuvanteds2pvaccinedemonstratesprotectioninhamstersandinducessystemiccellmediatedandmucosalimmunityinmice
AT acostahugo intranasalnanoemulsionadjuvanteds2pvaccinedemonstratesprotectioninhamstersandinducessystemiccellmediatedandmucosalimmunityinmice
AT brigolinchris intranasalnanoemulsionadjuvanteds2pvaccinedemonstratesprotectioninhamstersandinducessystemiccellmediatedandmucosalimmunityinmice
AT orangekallista intranasalnanoemulsionadjuvanteds2pvaccinedemonstratesprotectioninhamstersandinducessystemiccellmediatedandmucosalimmunityinmice
AT trabbickevin intranasalnanoemulsionadjuvanteds2pvaccinedemonstratesprotectioninhamstersandinducessystemiccellmediatedandmucosalimmunityinmice
AT chencharles intranasalnanoemulsionadjuvanteds2pvaccinedemonstratesprotectioninhamstersandinducessystemiccellmediatedandmucosalimmunityinmice
AT lienchiaen intranasalnanoemulsionadjuvanteds2pvaccinedemonstratesprotectioninhamstersandinducessystemiccellmediatedandmucosalimmunityinmice
AT linyijiun intranasalnanoemulsionadjuvanteds2pvaccinedemonstratesprotectioninhamstersandinducessystemiccellmediatedandmucosalimmunityinmice
AT linmeeiyun intranasalnanoemulsionadjuvanteds2pvaccinedemonstratesprotectioninhamstersandinducessystemiccellmediatedandmucosalimmunityinmice
AT chuangyashan intranasalnanoemulsionadjuvanteds2pvaccinedemonstratesprotectioninhamstersandinducessystemiccellmediatedandmucosalimmunityinmice
AT fattomali intranasalnanoemulsionadjuvanteds2pvaccinedemonstratesprotectioninhamstersandinducessystemiccellmediatedandmucosalimmunityinmice
AT bitkovira intranasalnanoemulsionadjuvanteds2pvaccinedemonstratesprotectioninhamstersandinducessystemiccellmediatedandmucosalimmunityinmice